GO:1902991 regulation of amyloid precursor protein catabolic process: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1902991 describes any process that modulates the frequency, rate or extent of amyloid precursor protein (APP) catabolic processing, a central event in Alzheimer's disease (AD) pathogenesis.
• APP catabolism is executed by sequential secretase cleavages: α-secretase (non-amyloidogenic), β-secretase/BACE1 and γ-secretase (amyloidogenic), producing Aβ peptides that aggregate in AD brains.
• Regulation occurs at multiple levels: APP trafficking and subcellular localization, secretase expression/activity, post-translational modifications such as lactylation at APP K612, and mitochondrial dynamics.
• APP and its fragments influence synaptic function, neurotransmitter release and mitochondrial transport, linking catabolic regulation to neuronal physiology beyond amyloid production.
• Dysregulation of APP catabolism is implicated in Alzheimer's disease, and APP metabolites contribute to mitochondrial and synaptic dysfunction.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal dissection of genes regulating APP catabolism and validation of therapeutic targets.
Description
The amyloid precursor protein (APP) is a type I transmembrane protein whose proteolytic processing gives rise to amyloid-β (Aβ) peptides, the principal component of amyloid plaques in Alzheimer's disease (AD). The term GO:1902991, regulation of amyloid precursor protein catabolic process, captures the diverse cellular mechanisms that control the breakdown of APP, including its cleavage by secretases, trafficking through membrane compartments, and degradation by lysosomal and proteasomal pathways. Because the balance between non-amyloidogenic and amyloidogenic APP catabolism directly determines Aβ production, understanding this regulatory node is central to AD research. Beyond Aβ generation, APP catabolic fragments participate in mitochondrial transport, synaptic vesicle release, and GABAergic transmission, underscoring the broad physiological importance of this process. Researchers studying GO:1902991 aim to identify the molecular switches that shift APP processing toward or away from amyloidogenesis, with the ultimate goal of therapeutic intervention.
regulation of amyloid precursor protein catabolic process At A Glance
| GO ID | GO:1902991 |
|---|---|
| GO term | regulation of amyloid precursor protein catabolic process |
| Ontology | biological_process |
| Synonym | regulation of APP catabolic process; regulation of amyloid precursor protein breakdown; regulation of amyloid precursor protein catabolism; regulation of amyloid precursor protein degradation; regulation of APP catabolism |
| Major function | Modulates the frequency, rate or extent of APP catabolic processing, thereby controlling the production of APP-derived fragments including Aβ |
| Related processes | APP trafficking, secretase activity, mitochondrial transport, neurotransmitter release |
| Disease relevance | Alzheimer's disease; amyloid pathology; synaptic dysfunction |
| Key enzymes | α-secretase, β-secretase (BACE1), γ-secretase complex |
| Regulatory modifications | APP lysine 612 lactylation |
What Is GO:1902991?
According to the Gene Ontology, GO:1902991 (regulation of amyloid precursor protein catabolic process) is defined as any process that modulates the frequency, rate or extent of amyloid precursor protein catabolic process. In other words, it encompasses all cellular and molecular events that control how APP is broken down, including the regulation of secretase-mediated cleavage, intracellular trafficking that determines substrate access to enzymes, and degradation of APP fragments. This term is a biological process and includes both positive and negative regulation of APP catabolism.
Why Is regulation of amyloid precursor protein catabolic process Important in Cell Biology?
GO:1902991 is critically important because the regulation of APP catabolism determines the production of amyloid-β, the peptide that accumulates in Alzheimer's disease brains and is thought to initiate a cascade of neurodegeneration. Moreover, APP catabolic fragments themselves have physiological roles in mitochondrial transport, synaptic function, and neurotransmitter release, so their regulated production impacts neuronal health beyond amyloidogenesis. Understanding this regulatory process offers opportunities for therapeutic intervention aimed at shifting APP processing toward non-amyloidogenic pathways.
• Controls the generation of amyloid-β peptides, central to Alzheimer's disease pathogenesis.
• Regulates the production of APP intracellular domain (AICD) and other fragments with signaling roles.
• Influences mitochondrial transport machinery and bioenergetics in neurons.
• Modulates neurotransmitter release through synapsin phosphorylation.
• Affects GABAergic transmission and network excitability.
• Post-translational modifications such as lactylation can alter APP processing and amyloid pathology.
• Trafficking of APP between organelles determines access to secretases and is a key regulatory node.
• Dysregulation is linked to sporadic and familial Alzheimer's disease.
• Provides targets for therapeutic strategies aiming to reduce amyloid burden.
• Serves as a paradigm for understanding regulated intramembrane proteolysis.
What Happens During regulation of amyloid precursor protein catabolic process?
APP trafficking and subcellular localization
In simple terms: Before APP can be cut, it must be in the right place inside the cell.
APP is synthesized in the endoplasmic reticulum and transported through the secretory pathway to the plasma membrane and endosomes. The regulation of its catabolism begins with trafficking: the residence time of APP in specific membrane compartments determines which secretases it encounters. For example, APP internalized into endosomes is more likely to be cleaved by β-secretase (BACE1) and γ-secretase, leading to Aβ production, whereas APP at the plasma membrane can be cleaved by α-secretase in the non-amyloidogenic pathway. Thus, proteins that regulate vesicular transport, such as sorting nexins and retromer components, indirectly modulate APP catabolism.
α-secretase-mediated non-amyloidogenic cleavage
In simple terms: One way to break down APP prevents the formation of amyloid-beta.
α-secretase cleaves APP within the Aβ domain, precluding Aβ generation and releasing soluble APPα (sAPPα). This cleavage is part of the non-amyloidogenic pathway and is regulated by enzymes such as ADAM10 and ADAM17. Factors that enhance α-secretase activity or APP colocalization with α-secretase shift catabolism away from amyloid production. The regulation of this step is therefore a key determinant of amyloidogenic potential.
β-secretase and γ-secretase-mediated amyloidogenic cleavage
In simple terms: The other way to cut APP produces the amyloid-beta peptide.
In the amyloidogenic pathway, β-secretase (BACE1) cleaves APP first, generating sAPPβ and a membrane-bound C99 fragment. C99 is then cleaved by the γ-secretase complex (presenilin, nicastrin, APH-1, PEN-2) at multiple sites to produce Aβ peptides of varying lengths, predominantly Aβ40 and Aβ42. The regulation of this sequential cleavage is tightly controlled by enzyme expression, subcellular localization, and accessory proteins. Dysregulation leads to increased Aβ42, which is more prone to aggregation.
Post-translational modifications of APP
In simple terms: Chemical tags on APP can change how it is processed.
APP undergoes various post-translational modifications that influence its catabolism. For instance, lactylation of APP at lysine 612 has been shown to ameliorate amyloid pathology and memory decline in Alzheimer's disease models, likely by altering APP processing. Other modifications such as phosphorylation, glycosylation, and ubiquitination also affect APP trafficking and cleavage. These modifications provide additional layers of regulation for GO:1902991.
Degradation of APP fragments and mitochondrial interactions
In simple terms: After APP is cut, the pieces must be cleared, and they can affect mitochondria.
Following cleavage, APP intracellular domain (AICD) and other fragments are degraded by proteasomal and lysosomal pathways. APP and its derived fragments can also localize to mitochondria and influence mitochondrial transport machinery, contributing to neuronal dysfunction when catabolism is altered. The regulation of APP catabolism thus extends to the clearance of its fragments and their impact on organelle function.
Key Genes Involved in GO:1902991 regulation of amyloid precursor protein catabolic process
The following genes and proteins are key players in the regulation of APP catabolic process, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| APP | Substrate of catabolic processing; source of Aβ and other fragments | Central to Alzheimer's disease; mutations cause familial AD |
| BACE1 | β-secretase; cleaves APP to initiate amyloidogenic pathway | Therapeutic target for reducing Aβ; knockout models show reduced amyloid |
| PSEN1 | Catalytic subunit of γ-secretase complex | Mutations cause familial AD; target for γ-secretase modulators |
| PSEN2 | Subunit of γ-secretase complex | Mutations linked to familial AD |
| NCSTN | Nicastrin; component of γ-secretase complex | Required for γ-secretase assembly and activity |
| APH1A | Component of γ-secretase complex | Stabilizes complex; affects Aβ production |
| PEN2 (PSENEN) | Component of γ-secretase complex | Essential for γ-secretase activity |
| ADAM10 | α-secretase; non-amyloidogenic cleavage of APP | Enhancing activity reduces Aβ; target for AD therapy |
| ADAM17 | α-secretase candidate; cleaves APP | Regulates non-amyloidogenic pathway |
| APOE | Lipid transport; influences APP catabolism and Aβ clearance | Major genetic risk factor for late-onset AD |
| SORL1 | Sorting receptor; regulates APP trafficking | Risk gene for AD; affects APP processing |
| SNX (sorting nexins) | Regulate endosomal sorting of APP | Modulate amyloidogenic cleavage |
| VPS35 | Retromer component; affects APP trafficking | Mutations linked to Parkinson's and AD |
| SYN1 (Synapsin) | Phosphorylation target downstream of APP; regulates neurotransmitter release | Links APP catabolism to synaptic function |
| MAPT (Tau) | Microtubule-associated protein; interacts with APP pathways | Tau pathology in AD; cross-talk with APP |
| LRP1 | Receptor for APP and Aβ; regulates clearance | Modulates APP catabolism and Aβ clearance |
| IDE | Insulin-degrading enzyme; degrades Aβ | Aβ clearance; affects amyloid burden |
How Is regulation of amyloid precursor protein catabolic process Regulated?
The regulation of APP catabolic process (GO:1902991) is itself controlled by multiple signaling pathways and cellular stressors. For example, APP lysine 612 lactylation acts as a regulatory modification that ameliorates amyloid pathology and memory decline, indicating that metabolic state can directly influence APP catabolism. Mitochondrial function and dynamics also impact APP processing, as APP and its fragments can alter mitochondrial transport machinery, and mitochondrial dysfunction may in turn affect APP catabolism. Additionally, neurotransmitter release mechanisms, such as synapsin phosphorylation, are influenced by APP, suggesting feedback between synaptic activity and APP processing. At the transcriptional level, secretase expression and trafficking regulators are modulated by various transcription factors, though specific pathways are still being elucidated.
regulation of amyloid precursor protein catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| APP | Alzheimer's disease; amyloid pathology | Knock-in of familial AD mutations (e.g., Swedish, London) in cell lines; overexpression |
| PSEN1 | Familial Alzheimer's disease | Knockout of PSEN1 to abolish γ-secretase activity; point mutations to model FAD |
| BACE1 | Alzheimer's disease; Aβ production | Knockout to reduce Aβ; overexpression to increase amyloidogenic processing |
| APOE | Late-onset Alzheimer's disease risk | Knock-in of APOE4 allele; knockout to study lipid metabolism |
| MAPT | Tauopathy; Alzheimer's disease | Knockout or point mutation (P301L) to study tau-APP interactions |
Alzheimer's disease
Alzheimer's disease is the most common neurodegenerative disorder and is characterized by amyloid plaques composed of Aβ peptides derived from APP catabolism. Dysregulation of GO:1902991, leading to increased production or reduced clearance of Aβ, is a central event in AD pathogenesis. Mutations in APP, PSEN1, and PSEN2 cause early-onset familial AD by altering APP processing to favor Aβ42 generation. Moreover, post-translational modifications such as APP lactylation can modulate amyloid pathology and memory deficits in AD models. Thus, targeting the regulation of APP catabolism is a major therapeutic strategy.
Mitochondrial dysfunction in neurodegeneration
APP and its derived fragments contribute to alterations in mitochondrial transport machinery, linking APP catabolism to mitochondrial dysfunction in Alzheimer's disease. The regulation of APP catabolism therefore impacts neuronal energy metabolism and viability, and dysregulation may exacerbate neurodegeneration beyond amyloid plaques.
Synaptic and network dysfunction
APP catabolic fragments influence neurotransmitter release through mechanisms involving synapsin phosphorylation, and overexpression of wild-type human APP alters GABAergic transmission. These findings indicate that the regulation of APP catabolism affects synaptic function and network excitability, which are disrupted in AD and other neurological conditions.
From regulation of amyloid precursor protein catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene alter APP catabolism and Aβ production? | CRISPR knockout in SH-SY5Y or HEK293 cells; measure Aβ by ELISA |
| Does a specific APP mutation affect processing? | Point mutation knock-in (e.g., APP K612 lactylation site) in cell lines |
| Does a risk variant in a trafficking gene affect APP localization? | Knock-in of the variant allele; imaging of APP trafficking |
| Can overexpression of a secretase shift APP processing? | Overexpression of BACE1 or ADAM10 in neuronal cells |
| How does APP catabolism affect mitochondrial transport? | Knockout of APP or expression of APP fragments; mitochondrial motility assays |
| Does APP catabolism regulate neurotransmitter release? | Overexpression of wild-type APP in primary neurons; electrophysiology |
How to Study the regulation of amyloid precursor protein catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Western blot | APP full-length and fragments (sAPPα, sAPPβ, C99, C83) | Assess catabolic pathway shifts |
| ELISA | Aβ40 and Aβ42 levels | Quantify amyloidogenic processing |
| Immunofluorescence | APP localization and colocalization with secretases | Study trafficking regulation |
| Live-cell imaging | Mitochondrial transport dynamics | Evaluate APP fragment effects on mitochondria |
| Electrophysiology | Synaptic transmission and plasticity | Link APP catabolism to network function |
| Phospho-immunoblot | Synapsin phosphorylation | Measure downstream signaling |
| qRT-PCR | Secretase mRNA levels | Assess transcriptional regulation |
| CRISPR screening | Identify regulators of APP catabolism | Unbiased discovery of novel genes |
Measuring APP catabolic products
Western blotting with antibodies against APP, sAPPα, sAPPβ, C99, C83, and Aβ is commonly used to assess APP catabolism. ELISA kits specifically detect Aβ40 and Aβ42, allowing quantification of amyloidogenic processing. These methods are essential for evaluating the impact of genetic perturbations on GO:1902991.
Imaging APP trafficking and localization
Fluorescence microscopy of tagged APP (e.g., GFP-APP) enables tracking of APP trafficking between the plasma membrane, endosomes, and Golgi. Colocalization with organelle markers and secretases provides insight into regulatory mechanisms. Live-cell imaging can reveal dynamic changes in APP distribution upon genetic manipulation.
Assessing mitochondrial function and transport
Mitochondrial transport assays using fluorescently labeled mitochondria in neurons can measure the impact of APP and its fragments on mitochondrial motility. Seahorse analysis or ATP measurements assess bioenergetics. These methods link APP catabolism to mitochondrial dysfunction.
Synaptic function and neurotransmitter release
Electrophysiology and neurotransmitter release assays (e.g., synaptosome preparations) evaluate how APP catabolism affects synaptic transmission. Phosphorylation of synapsin can be monitored by immunoblotting to assess downstream effects. These approaches connect GO:1902991 to neuronal network activity.
How CRISPR Can Be Used to Study GO:1902991 regulation of amyloid precursor protein catabolic process
Knockout
CRISPR knockout of candidate genes (e.g., BACE1, ADAM10, SORL1) in neuronal cell lines or primary neurons allows assessment of their necessity for APP catabolism. Knockout of APP itself serves as a control for fragment-specific effects. Measuring Aβ and APP fragments by ELISA and western blot reveals the impact on GO:1902991.
Point Mutation
Introducing point mutations such as APP K612 (lactylation site) or familial AD mutations (e.g., APP Swedish) via CRISPR base editing or HDR enables precise interrogation of regulatory modifications. These models help determine how specific residues affect APP processing and amyloid pathology.
Knock-in
Knock-in of disease-associated variants (e.g., APOE4, PSEN1 mutations) or tagging of endogenous APP with fluorescent or affinity tags allows study of APP catabolism in a physiological context. Tagged knock-in lines facilitate trafficking studies and interactome analysis.
Overexpression
Overexpression of wild-type or mutant APP, BACE1, or ADAM10 in cell models can drive amyloidogenic or non-amyloidogenic processing, respectively. Overexpression of wild-type human APP alters GABAergic transmission, demonstrating functional consequences. These models are useful for screening modulators of APP catabolism.
How EDITGENE Supports regulation of amyloid precursor protein catabolic process Research
Researchers studying regulation of amyloid precursor protein catabolic process-related genes often need to determine whether a candidate gene is causally involved in APP processing, whether a specific mutation alters catabolism, or whether overexpression mimics a pathological state. EDITGENE provides a comprehensive suite of CRISPR-based services to address these questions with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for regulation of amyloid precursor protein catabolic process research.
Frequently Asked Questions About regulation of amyloid precursor protein catabolic process
What is GO:1902991?
GO:1902991 is a Gene Ontology biological process term defined as any process that modulates the frequency, rate or extent of amyloid precursor protein catabolic process.
What genes are involved in regulation of amyloid precursor protein catabolic process?
Key genes include APP, BACE1, PSEN1, PSEN2, NCSTN, APH1A, PEN2, ADAM10, ADAM17, APOE, SORL1, and VPS35, among others.
How is APP catabolism regulated?
APP catabolism is regulated by trafficking, secretase activity, post-translational modifications such as lactylation, and mitochondrial interactions.
What is the role of BACE1 in APP catabolism?
BACE1 is the β-secretase that cleaves APP to initiate the amyloidogenic pathway, producing sAPPβ and C99, which is further cleaved to Aβ.
What is the difference between amyloidogenic and non-amyloidogenic APP processing?
Amyloidogenic processing involves β- and γ-secretases and produces Aβ, while non-amyloidogenic processing involves α-secretase and precludes Aβ formation.
How does APP lactylation affect Alzheimer's disease?
APP lysine 612 lactylation ameliorates amyloid pathology and memory decline in Alzheimer's disease models, suggesting a protective regulatory modification.
Can CRISPR be used to study APP catabolism?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable precise dissection of genes regulating APP catabolism.
What cell models are used to study APP catabolism?
Common models include SH-SY5Y, HEK293, and primary neurons, often with APP or secretase overexpression or knockout.
How is APP catabolism measured?
It is measured by western blot for APP fragments, ELISA for Aβ40/Aβ42, and imaging for trafficking.
What diseases are linked to dysregulation of APP catabolism?
Alzheimer's disease is the primary disease, with additional links to mitochondrial dysfunction and synaptic disorders.
Conclusion
GO:1902991, regulation of amyloid precursor protein catabolic process, is a critical biological process that controls the production of amyloid-β and other APP-derived fragments. Its dysregulation is central to Alzheimer's disease pathogenesis, and it intersects with mitochondrial function, synaptic transmission, and post-translational modifications. Understanding the molecular players and regulatory mechanisms offers promising avenues for therapeutic intervention. EDITGENE provides advanced CRISPR tools to investigate this process and accelerate drug discovery.
References
- 1. Hur JY. 2022. γ-Secretase in Alzheimer's disease.. Exp Mol Med 54(4):433-446 PMID: 35396575
- 2. De-Paula VJ et al.. 2012. Alzheimer's disease.. Subcell Biochem 65:329-52 PMID: 23225010
- 3. Tian Q et al.. 2025. APP lysine 612 lactylation ameliorates amyloid pathology and memory decline in Alzheimer's disease.. J Clin Invest 135(1) PMID: 39744941
- 4. Vaillant-Beuchot L et al.. 2024. The amyloid precursor protein and its derived fragments concomitantly contribute to the alterations of mitochondrial transport machinery in Alzheimer's disease.. Cell Death Dis 15(5):367 PMID: 38806484
- 5. Strope TA et al.. 2023. Amyloid precursor protein and mitochondria.. Curr Opin Neurobiol 78:102651 PMID: 36462447
- 6. Liu A et al.. 2019. Regulation of Neurotransmitter Release by Amyloid Precursor Protein Through Synapsin Phosphorylation.. Neurochem Res 44(3):683-691 PMID: 29052089
- 7. Mañucat-Tan NB et al.. 2019. Cellular Trafficking of Amyloid Precursor Protein in Amyloidogenesis Physiological and Pathological Significance.. Mol Neurobiol 56(2):812-830 PMID: 29797184
- 8. Kreis A et al.. 2021. Overexpression of wild-type human amyloid precursor protein alters GABAergic transmission.. Sci Rep 11(1):17600 PMID: 34475508
